Persistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction

References

1. 1.↵
   1. Lee TA,
   2. Bartle B,
   3. Weiss KB

   . Spirometry use in clinical practice following diagnosis of COPD. Chest 2006;129(6):1509–1515.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Collins BF,
   2. Feemster LC,
   3. Rinne ST,
   4. Au DH

   . Factors predictive of airflow obstruction among veterans with presumed empiric diagnosis and treatment of COPD. Chest 2015;147(2):369–376.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Collins BF,
   2. Ramenofsky D,
   3. Au DH,
   4. Ma J,
   5. Uman JE,
   6. Feemster LC

   . The association of weight with the detection of airflow obstruction and inhaled treatment among patients with a clinical diagnosis of COPD. Chest 2014;146(6):1513–1520.

   OpenUrlPubMed
4. 4.↵
   1. Han MK,
   2. Kim MG,
   3. Mardon R,
   4. Renner P,
   5. Sullivan S,
   6. Diette GB,
   7. Martinez FJ

   . Spirometry utilization for COPD: how do we measure up? Chest 2007;132(2):403–409.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Fortis S,
   2. Kittah J,
   3. De Aguirre M,
   4. Plataki M,
   5. Wolff A,
   6. Amoateng-Adjepong Y,
   7. Manthous CA

   . Perseverant, non-indicated treatment of obese patients for obstructive lung disease. BMC Pulm Med 2013;13:68.

   OpenUrlPubMed
6. 6.↵
   1. Pellegrino R,
   2. Viegi G,
   3. Brusasco V,
   4. Crapo RO,
   5. Burgos F,
   6. Casaburi R,
   7. et al

   . Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948–968.

   OpenUrlFREE Full Text
7. 7.↵
   1. Hyatt RE,
   2. Cowl CT,
   3. Bjoraker JA,
   4. Scanlon PD

   . Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 2009;135(2):419–424.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Fortis S,
   2. Corazalla EO,
   3. Wang Q,
   4. Kim HJ

   . The difference between slow and forced vital capacity increases with increasing body mass index: a paradoxical difference in low and normal body mass indices. Respir Care 2015;60(1):113–118.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Miller MR,
   2. Crapo R,
   3. Hankinson J,
   4. Brusasco V,
   5. Burgos F,
   6. Casaburi R,
   7. et al

   . General considerations for lung function testing. Eur Respir J 2005;26(1):153–161.

   OpenUrlFREE Full Text
10. 10.
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al

    . Standardisation of spirometry. Eur Respir J 2005;26(2):319–338.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Wanger J,
    2. Clausen JL,
    3. Coates A,
    4. Pedersen OF,
    5. Brusasco V,
    6. Burgos F,
    7. et al

    . Standardisation of the measurement of lung volumes. Eur Respir J 2005;26(3):511–522.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Iyer VN,
    2. Schroeder DR,
    3. Parker KO,
    4. Hyatt RE,
    5. Scanlon PD

    . The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest 2011;139(4):878–886.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Hankinson JL,
    2. Odencrantz JR,
    3. Fedan KB

    . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159(1):179–187.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Quanjer PH,
    2. Tammeling GJ,
    3. Cotes JE,
    4. Pedersen OF,
    5. Peslin R,
    6. Yernault JC

    . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.

    OpenUrlWeb of Science
15. 15.↵
    1. García-Rio F,
    2. Soriano JB,
    3. Miravitlles M,
    4. Muñoz L,
    5. Duran-Tauleria E,
    6. Sánchez G,
    7. et al

    . Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011;139(5):1072–1080.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Wan ES,
    2. Hokanson JE,
    3. Murphy JR,
    4. Regan EA,
    5. Make BJ,
    6. Lynch DA,
    7. et al

    . Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med 2011;184(1):57–63.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Casanova C,
    2. Cote C,
    3. de Torres JP,
    4. Aguirre-Jaime A,
    5. Marin JM,
    6. Pinto-Plata V,
    7. Celli BR

    . Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(6):591–597.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.
    1. Cooper CB

    . The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006;119(10 Suppl 1):21–31.

    OpenUrlCrossRefPubMed
19. 19.
    1. O'Donnell DE

    . Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3(2):180–184.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Mets OM,
    2. de Jong PA,
    3. van Ginneken B,
    4. Kruitwagen CL,
    5. Prokop M,
    6. Oudkerk M,
    7. et al

    . CT air trapping is independently associated with lung function reduction over time. PLoS One 2013;8(4):e61783.

    OpenUrlPubMed
21. 21.↵
    1. Teodorescu M,
    2. Barnet JH,
    3. Hagen EW,
    4. Palta M,
    5. Young TB,
    6. Peppard PE

    . Association between asthma and risk of developing obstructive sleep apnea. JAMA 2015;313(2):156–164.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Zamarrón C,
    2. García Paz V,
    3. Morete E,
    4. del Campo Matías F

    . Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis 2008;3(4):671–682.

    OpenUrlPubMed
23. 23.↵
    1. Camp PG,
    2. Goring SM

    . Gender and the diagnosis, management, and surveillance of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4(8):686–691.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Lebeau JP,
    2. Cadwallader JS,
    3. Aubin-Auger I,
    4. Mercier A,
    5. Pasquet T,
    6. Rusch E,
    7. et al

    . The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract 2014;15:130.

    OpenUrlPubMed
25. 25.↵
    1. Tashkin DP,
    2. Leimer I,
    3. Metzdorf N,
    4. Decramer M

    . Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT trial. Respir Res 2015;2(16)65. doi: 10.1186/s12931-015-0216-4.

    OpenUrl
26. 26.↵
    1. Calverley PM,
    2. Anderson JA,
    3. Celli B,
    4. Ferguson GT,
    5. Jenkins C,
    6. Jones PW,
    7. et al

    . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775–789.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Lutchmedial SM,
    2. Creed WG,
    3. Moore AJ,
    4. Walsh RR,
    5. Gentchos GE,
    6. Kaminsky DA

    . How common is airflow limitation in patients with emphysema on computerized tomography of the chest? Chest 2015;148(1):176–184.

    OpenUrlCrossRefPubMed